0001193125-26-192574
SEC filingStrong operational performance with revenue growth and significant margin expansion, driven by favorable mix and cost controls, though restructuring charges and FX headwinds remain.
Revenue for the first quarter of 2026 was $677.3 million, up 7.2% from $631.8 million in the same period last year. The increase was primarily due to higher demand in the Medical and Semi-Cap sectors, partially offset by lower demand in the Industrial sector. The company continues to benefit from new program wins and its turnkey product realization capabilities, which support customers from concept through volume production.
Net income increased 257.4% to $13.0 million, or $0.36 per diluted share, compared to $3.6 million, or $0.10 per diluted share, in the prior year. The significant improvement was driven by higher operating income and lower interest expense, partially offset by higher income tax expense.
The company continues to focus on human capital and operational excellence to maintain competitiveness. Risks include demand softness from certain customers, timing of customer demand and order fulfillment, and supply chain premiums for excess component costs. Dividend payments are not guaranteed, and the company may adjust its capital allocation strategy based on market conditions.